An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The study found phenylacetylglutamine (PAG), produced by gut bacteria ...
Cleveland Clinic researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The Nature Communications study found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results